

Regimen Reference Order – THOR – atezolizumab

ARIA: LUNG – [atezolizumab]

Planned Course: Every 21 days until disease progression or unacceptable toxicity

Indication for Use: Non-Small Cell Lung Cancer (NSCLC) Metastatic

Drug Alert: Immune Checkpoint Inhibitor

CVAD: At Provider’s Discretion

Proceed with treatment if:

- *ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $50 \times 10^9/L$*
- *AST/ALT less than 3 times upper limit of normal*
- *Total bilirubin less than 1.5 times upper limit of normal*
- *Creatinine clearance greater than 30 mL/min*
- ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – THOR – atezolizumab

Establish primary solution 500 mL of: normal saline		
Drug	Dose	CCMB Administration Guideline
atezolizumab	1200 mg (standard dose)	IV in normal saline 250 mL <ul style="list-style-type: none"> • Dose 1 to be infused over 60 minutes • Dose 2 and subsequent to be infused over 30 minutes (if first dose well tolerated)

Flush after each medication:

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, AST, ALT, total bilirubin, albumin, glucose, sodium, potassium, calcium, magnesium, phosphate, TSH and T4 as per Physician Orders
- Medical oncologist or designate (i.e. family practitioner in oncology) must assess patient for immune-mediated adverse reactions prior to each cycle
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required
- Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications		
Drug	Dose	CCMB Administration Guideline
Not Applicable		

DISCHARGE INSTRUCTIONS

- Confirm that patient has received the CCMB Immune Checkpoint Inhibitor Medical Alert wallet card
- Reinforce to patient the immune-mediated adverse reactions and importance of reporting immediately
 - For severe symptoms, the patient should be instructed to go to the nearest emergency room. Oncologist on call should be contacted

ADDITIONAL INFORMATION

- atezolizumab is an Immune Checkpoint Inhibitor. Consult with oncologist for immune-mediated adverse reactions; corticosteroids are often indicated